QTX-3046 is under clinical development by Quanta Therapeutics and currently in Phase I for Colorectal Cancer. According to GlobalData, Phase I drugs for Colorectal Cancer have a 7 ...

QTX-3046 is under clinical development by Quanta Therapeutics and currently in Phase I for Lung Cancer. According to GlobalData, Phase I drugs for Lung Cancer have a 78% phase tra ...

Additionally, the Phase 1 clinical trial evaluating QTX3034, an oral G12D-preferring multi-KRAS inhibitor, as a monotherapy and in combination with cetuximab, continues to enroll patients, and data is ...

Acellera Therapeutics, a pioneer in computational chemistry and AI-driven drug discovery, today announced the launch of ...

Quantum eMotion (TSXV: QNC) (OTCQB: QNCCF) (QeM) recently announced the commercialization of its quantum-powered security ...

Keep an eye on the first patient dosed in phase 1 and 2 trials of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD),with ...

Acellera Therapeutics, a pioneer in computational ... model designed to deliver quantum-level accuracy for predicting atomic interactions—an essential factor in identifying promising drug ...

Company today announced a major strategic step forward as it explores new growth avenuesArtificial Intelligence (AI) and ...

As the digital therapeutics field continues to revolutionize healthcare ... QeM has become a pioneering force in classical and quantum cybersecurity solutions thanks to its patented Quantum Random ...

Quanta receives US FDA clearance to begin phase 1 trial of QTX3544, an oral G12V-preferring, dual ON/OFF state, multi-KRAS inhibitor: Radnor, Pennsylvania Friday, January 10, 2025 ...

As the digital therapeutics field continues to revolutionize ... and scalability across diverse healthcare systems. About QeM ( %Quantum eMotion Corp.) The Company aims to address the growing ...